Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0028961 (
oliguria
)
1,847
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ninety-three thromboembolic occlusions of peripheral arteries or grafts in 85 patients were treated with high-dose urokinase by direct intraarterial infusion.
Urokinase
was infused at 4000 IU/min until antegrade blood flow was reestablished and then at 1000 or 2000 IU/min until clot lysis was completed. Of the 93 infusions, 75 (81%) resulted in clinical improvement. The infusion therapy was incomplete in nine patients. The mean duration of the 84 completed infusions was 18 +/- 20 hr, the incidence of complete clot lysis was 83%, and the incidence of clinical improvement was 89%. Significant bleeding, requiring transfusion, occurred during or after four of the urokinase infusions (4%). Other complications included distad clot migration, thrombus formation on the catheter, revascularization phenomena,
oliguria
, skin rash, pseudoaneurysm, balloon rupture during angioplasty, and vascular spasm. There were no instances of drug resistance or adverse drug reactions. These results indicate that an initially high-dose urokinase regimen accomplishes more rapid recanalization, a higher incidence of total clot lysis, and produces fewer complications than the standard low-dose streptokinase regimen.
...
PMID:Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase. 387 36